Patients
ASPARLAS ONCASPAR TIBSOVO VORANIGO
Treatment Resources Contact Us
Healthcare Providers
ASPARLAS ONCASPAR TIBSOVO VORANIGO
Treatment Resources Contact Us
Patients
Healthcare Providers
Treatment Specific Support ASPARLAS ONCASPAR TIBSOVO VORANIGO
Treatment Resources
Contact Us

Click logo for Important Safety Information.

Patient Financial Support for ONCASPAR®
750 U/ml powder for solution for injection/infusion

ServierONE connects your patients to the right support programs and services that may help them access ONCASPAR 750 U/ml powder for solution for injection/infusion.

We offer:

  • Support with insurance coverage and reimbursement
  • Financial assistance to help eligible patients pay for ONCASPAR 750 U/ml powder for solution for injection/infusion
  • Access to a one-on-one Patient Experience Manager

Your ONCASPAR 750 U/ml powder for solution for injection/infusion Ordering Experience

Select:
About ONCASPAR 750 U/ml powder for solution for injection/infusion FAQ Patient Assistance Program Ordering Portal Ordering Portal Training

About ONCASPAR® 750 U/ml powder for solution for injection/infusion

To ensure continued access to prescribed medication, the FDA has granted discretionary use of the lyophilized (freeze-dried) version of ONCASPAR. Patients previously receiving the liquid formulation of ONCASPAR may now receive ONCASPAR 750 U/ml powder for solution for injection/infusion.

ONCASPAR 750 U/ml powder for solution for injection/infusion can be administered via intravenous (IV) infusion or intramuscular (IM) injection, with an updated premedication regimen. Staff are recommended to review reconstitution and dilution guides, premedication protocols, and information on ordering and storage.

Servier is committed to making sure patients can continue treatment without interruption.

If you have questions, please call 1-800-813-5905 , Monday through Friday, 8 AM to 8 PM ET.

ONCASPAR 750 U/ml powder for solution for injection/infusion is a lyophilized (freeze-dried) formulation, which contains the same active ingredient as liquid ONCASPAR (pegaspargase). While it requires different preparation, ONCASPAR 750 U/ml powder for solution for injection/infusion has demonstrated comparable safety and efficacy.

Due to a temporary shortage of the liquid formulation, the FDA has granted discretionary use of the lyophilized formulation to ensure continued access to this medication.

  • Routes: IV infusion over 1–2 hours, or IM injection.  
  • Dosing:
    • Adults >21 years: 2,000 U/m² every 14 days.
    • ≤21 years, BSA ≥0.6 m²: 2,500 U/m² every 14 days.
    • BSA <0.6 m²: 82.5 U/kg every 14 days.
  • Premedication: Acetaminophen, H1 and H2 blockers 30–60 minutes before administration.
  • Keep unopened vials refrigerated at 2–8 °C. Do not freeze; protect from light.  
  • The reconstituted solution is stable for 24 hours below 25 °C. 
  • The diluted solution is stable for 48 hours at 2–8 °C. 
  • Use reconstituted and diluted solutions immediately whenever possible.  
  • Infusion bags should be protected from sunlight.

The ordering process remains unchanged for HCPs and institutions. Patient eligibility criteria remain the same as for liquid ONCASPAR.  

Healthcare providers should review reconstitution/dilution guides, premedication protocols, and information on ordering/storage, to help patients smoothly transition to the new formulation. 

We leave that to the institution’s discretion. It is whoever the facility deems to be administrator. This person will have the authority to add/remove other users as needed.

No, ASPARLAS will continue to follow its current process through Cardinal Health Specialty Distributor. Orders can be placed through our exclusive arrangement by calling 855-855-0708 or 866-476-1340.

Yes, an institution can have multiple administrators and users. When the administrator(s) is logged into the portal, they can go to "User Administration" within the portal to add additional users.

You will need the institution's NPI for your affiliated organization to register for the ServierONE Eligibility Ordering Portal. ServierONE does not require the NPI of a healthcare professional to register.

If you have questions, please call 1-800-813-5905 , Monday through Friday, 8 AM to 8 PM ET.

ONCASPAR® 750 U/ml powder for solution for injection/infusion Patient Assistance Program (PAP)

The Patient Assistance Program (PAP) helps uninsured and underinsured patients access important treatments. The formulation change from ONCASPAR to ONCASPAR 750 U/ml powder for solution for injection/infusion will not impact this program. For existing patients, the benefits of PAP are valid for one year.

New patients may be eligible for PAP if they meet the following criteria:
  • U.S./Puerto Rico resident
  • Commercially, privately, or government insured
  • Uninsured or underinsured
  • Household gross annual income does not exceed 600% of the US Federal Poverty Level to qualify financially
  • If you have questions about qualifying, call us at 1-800-813-5905 for further assistance

Healthcare Providers will need to call 1-800-813-5905 to receive the Patient Enrollment Form and work with their patient to complete.

Call 1-800-813-5905 to Begin Enrollment

Call 1-800-813-5905 to Begin Enrollment

Fax completed forms to ServierONE Patient Services Program at 1-844-882-9845.

How to enroll in the ONCASPAR 750 U/ml powder for solution for injection/infusion Patient Assistance Program (PAP)

Step 1

1. Prescription & Enrollment Form
Call ServierONE to obtain the ONCASPAR 750 U/ml powder for solution for injection/infusion Enrollment Form. Then complete the Enrollment Form and fax it to ServierONE at 1-844-882-9845.

Step 2

2. Benefit Investigation
One of our ServierONE team members will explore insurance coverage. If your patient is uninsured or ONCASPAR 750 U/ml powder for solution for injection/infusion is not covered by their insurance, you will proceed to the next step.

Step 3

3. Financial Criteria/Qualifications
One of our ServierONE team members will confirm that your patient meets the eligibility criteria for PAP.

Step 4

4. Enrollment Complete
If your patient is approved, they will be enrolled in PAP for a rolling year.

If you have questions or need assistance, contact ServierONE Patient Support Program.

Please call 1-800-813-5905, Monday through Friday, 8 AM to 8 PM ET.
Or email us at USPatientServices@servier.com.

Key Features

Overview: The program is dedicated to assisting uninsured or underinsured patients by offering medication to those who meet our eligibility criteria.

Income Eligibility: The ServierONE Patient Assistance Program is available to patients who meet specific income criteria, ensuring that those in financial need can benefit from the program.

Application Support: Our dedicated program representatives are available to support patients with the application process, including guidance on required documentation and eligibility requirements.

Renewable Benefits: Qualified patients may receive ongoing support through the Servier Patient Assistance Program, ensuring continued access to treatment as needed.

If you have questions, please call 1-800-813-5905 , Monday through Friday, 8 AM to 8 PM ET.

Convenient Online ONCASPAR® 750 U/ml powder for solution for injection/infusion Ordering Portal

Ordering through the portal is simple.

  1. Register your organization and create a user account
  2. Check patient eligibility and receive an ordering code for eligible patients
  3. Call Cardinal Health to place an order using the ordering code

All ONCASPAR 750 U/ml powder for solution for injection/infusion orders will need to be processed through the Ordering Portal.

For detailed instructions on how to access the Ordering Portal for ONCASPAR 750 U/ml powder for solution for injection/infusion, go the ONCASPAR Training section. The process is the same for both formulations.

Go to ordering portal

Go to ordering portal

If you have questions, please call 1-800-813-5905 , Monday through Friday, 8 AM to 8 PM ET.

Guides for Using the ONCASPAR® 750 U/ml powder for solution for injection/infusion Ordering Portal

To help simplify the ordering process, we offer multiple resources that walk you through the process.

For detailed explanations of how the Ordering Portal works, please use one of our guides.

Instructions for Using the ONCASPAR 750 U/ml powder for solution for injection/infusion Ordering Portal

Step 1

Register your organization and create a user account at www.oncasparportal.com
Your organization’s first registered user will be the portal administrator. You will need the following information from your organization:

  • NPI
  • Address
  • Key contact information

Once your registration has been submitted, you will receive an email regarding the status within 1 business day

Registration is required to use the portal

Access the portal here

Access the portal here

Step 2

Check patient eligibility and receive an ordering code for eligible patients
Once logged in, you will be directed to the patient eligibility page. You will need the following patient information:

  • Patient ID from your system
  • Date of birth
  • Total anticipated vial(s) for duration of therapy
If the patient is determined eligible, you will be provided with an ordering code that is specific to the patient and will be required when calling Cardinal Health
If the patient is determined ineligible and you have questions about the result, contact us at 1-800-813-5905

The ordering code is required to place an order for ONCASPAR 750 U/ml powder for solution for injection/infusion with Cardinal Health. Please remember to save the ordering code within the patient’s medical record for future orders of ONCASPAR 750 U/ml powder for solution for injection/infusion

Step 3

Call Cardinal Health to place an order using the ordering code
Provide the ordering code to Cardinal Health to finish placing the order.

Note: This step has not changed from the previous ordering process.

Cardinal Health contact information for ordering

  • Phone: 1-855-740-1867
  • Hours of operation: Monday-Friday, 7 am to 6 pm CT
  • If your order is placed after 4pm CT it will be processed the next business day.
  • If placing an order within Puerto Rico, contact Cardinal Health Puerto Rico:

Learn more about how to use the Ordering Portal by reviewing our Frequently Asked Questions (FAQ) .

If you have questions, please call 1-800-813-5905 , Monday through Friday, 8 AM to 8 PM ET.

ONCASPAR® INDICATIONS AND IMPORTANT SAFETY INFORMATION

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

  • History of serious hypersensitivity reactions, including anaphylaxis, to ONCASPAR (pegaspargase) or to any of the excipients.
  • History of serious thrombosis with prior L-asparaginase therapy.
  • History of pancreatitis, including pancreatitis related to prior L-asparaginase therapy.
  • History of serious hemorrhagic events with prior L-asparaginase therapy.
  • Severe hepatic impairment.

WARNINGS and PRECAUTIONS

Anaphylaxis and Serious Hypersensitivity Reactions: Anaphylaxis and serious hypersensitivity reactions can occur. The risk of serious hypersensitivity reactions is higher in patients with known hypersensitivity to (E.) coli derived L-asparaginase formulations. Premedicate patients 30-60 minutes prior to administration of ONCASPAR. Observe patients for 1 hour after administration in a setting with resuscitation equipment and other agents necessary to treat anaphylaxis. Discontinue ONCASPAR in patients with serious hypersensitivity reactions.

Thrombosis: Serious thrombotic events, including sagittal sinus thrombosis, can occur. Discontinue ONCASPAR in patients with serious thrombotic events.

Pancreatitis: Pancreatitis can occur. Fatal outcomes have been reported. Inform patients of the signs and symptoms of pancreatitis, which, if left untreated, could be fatal. Discontinue ONCASPAR in patients where pancreatitis is suspected. If pancreatitis is confirmed, do not resume ONCASPAR.

Glucose Intolerance: Glucose intolerance can occur and, in some cases, be irreversible. Monitor serum glucose.

Hemorrhage: Increased prothrombin time (PT), increased partial thromboplastin time (PTT), and hypofibrinogenemia can occur. Evaluate patients with signs and symptoms of hemorrhage with coagulation parameters including PT, PTT, and fibrinogen. Consider appropriate replacement therapy in patients with severe or symptomatic coagulopathy. Discontinue ONCASPAR for severe or life-threatening hemorrhage.

Hepatotoxicity: Hepatotoxicity, including severe, life-threatening, and potentially fatal cases of hepatic veno-occlusive disease (VOD), have been observed in patients treated with ONCASPAR in combination with standard chemotherapy, including during the induction phase of multiphase chemotherapy. Do not administer ONCASPAR to patients with severe hepatic impairment. Evaluate bilirubin and transaminases prior to each dose of ONCASPAR and at least weekly, during cycles of treatment that include ONCASPAR, through 6 weeks after the last dose of ONCASPAR. Monitor frequently for signs and symptoms of hepatic VOD, which may include rapid weight gain, fluid retention with ascites, hepatomegaly (which may be painful), and rapid increase of bilirubin. For patients who develop abnormal liver tests after ONCASPAR, more frequent monitoring for liver test abnormalities and clinical signs and symptoms of VOD is recommended. In the event of serious liver toxicity, including VOD, discontinue treatment with ONCASPAR and provide supportive care.

ADVERSE REACTIONS
The most common grade 3 and 4 adverse reactions with ONCASPAR (>5%) included hypoalbuminemia, elevated transaminase, febrile neutropenia, hypertriglyceridemia, hyperglycemia, bilirubin increased, pancreatitis, abnormal clotting studies, embolic and thrombotic events, hypersensitivity, sepsis, and infections.

Please see the accompanying ONCASPAR Full Prescribing Information.

ONCASPAR is a registered trademark of Servier IP UK Ltd., a wholly-owned, indirect subsidiary of Les Laboratoires Servier. Servier and the Servier logo are trademarks of Les Laboratoires Servier.

INDICATIONS AND USAGE

ONCASPAR® (pegaspargase) is indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of pediatric and adult patients with:

  • First-line acute lymphoblastic leukemia (ALL)
  • ALL and hypersensitivity to native forms of L-asparaginase

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

  • History of serious hypersensitivity reactions, including anaphylaxis, to ONCASPAR (pegaspargase) or to any of the excipients.
  • History of serious thrombosis with prior L-asparaginase therapy.
  • History of pancreatitis, including pancreatitis related to prior L-asparaginase therapy.
  • History of serious hemorrhagic events with prior L-asparaginase therapy.
  • Severe hepatic impairment.

WARNINGS and PRECAUTIONS

Anaphylaxis and Serious Hypersensitivity Reactions: Anaphylaxis and serious hypersensitivity reactions can occur. The risk of serious hypersensitivity reactions is higher in patients with known hypersensitivity to (E.) coli derived L-asparaginase formulations. Premedicate patients 30-60 minutes prior to administration of ONCASPAR. Observe patients for 1 hour after administration in a setting with resuscitation equipment and other agents necessary to treat anaphylaxis. Discontinue ONCASPAR in patients with serious hypersensitivity reactions.

Thrombosis: Serious thrombotic events, including sagittal sinus thrombosis, can occur. Discontinue ONCASPAR in patients with serious thrombotic events.

Pancreatitis: Pancreatitis can occur. Fatal outcomes have been reported. Inform patients of the signs and symptoms of pancreatitis, which, if left untreated, could be fatal. Discontinue ONCASPAR in patients where pancreatitis is suspected. If pancreatitis is confirmed, do not resume ONCASPAR.

Glucose Intolerance: Glucose intolerance can occur and, in some cases, be irreversible. Monitor serum glucose.

Hemorrhage: Increased prothrombin time (PT), increased partial thromboplastin time (PTT), and hypofibrinogenemia can occur. Evaluate patients with signs and symptoms of hemorrhage with coagulation parameters including PT, PTT, and fibrinogen. Consider appropriate replacement therapy in patients with severe or symptomatic coagulopathy. Discontinue ONCASPAR for severe or life-threatening hemorrhage.

Hepatotoxicity: Hepatotoxicity, including severe, life-threatening, and potentially fatal cases of hepatic veno-occlusive disease (VOD), have been observed in patients treated with ONCASPAR in combination with standard chemotherapy, including during the induction phase of multiphase chemotherapy. Do not administer ONCASPAR to patients with severe hepatic impairment. Evaluate bilirubin and transaminases prior to each dose of ONCASPAR and at least weekly, during cycles of treatment that include ONCASPAR, through 6 weeks after the last dose of ONCASPAR. Monitor frequently for signs and symptoms of hepatic VOD, which may include rapid weight gain, fluid retention with ascites, hepatomegaly (which may be painful), and rapid increase of bilirubin. For patients who develop abnormal liver tests after ONCASPAR, more frequent monitoring for liver test abnormalities and clinical signs and symptoms of VOD is recommended. In the event of serious liver toxicity, including VOD, discontinue treatment with ONCASPAR and provide supportive care.

ADVERSE REACTIONS
The most common grade 3 and 4 adverse reactions with ONCASPAR (>5%) included hypoalbuminemia, elevated transaminase, febrile neutropenia, hypertriglyceridemia, hyperglycemia, bilirubin increased, pancreatitis, abnormal clotting studies, embolic and thrombotic events, hypersensitivity, sepsis, and infections.

Please see the accompanying ONCASPAR Full Prescribing Information.

ONCASPAR is a registered trademark of Servier IP UK Ltd., a wholly-owned, indirect subsidiary of Les Laboratoires Servier. Servier and the Servier logo are trademarks of Les Laboratoires Servier.

INDICATIONS AND USAGE

ONCASPAR® (pegaspargase) is indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of pediatric and adult patients with:

  • First-line acute lymphoblastic leukemia (ALL)
  • ALL and hypersensitivity to native forms of L-asparaginase

© 2025 Servier Pharmaceuticals LLC. Boston, MA 02210. Customer Service: 1-800-807-6124.
Servier and the Servier Logo are registered trademarks of LES LABORATOIRES SERVIER.
All other trademarks, registered or unregistered, are the property of their respective owners.
US-PAT-00318 01/26

Chat bubble

Support Bot

Online

This information is intended for U.S. Healthcare Professionals only. Click the CONTINUE button below to go to the page requested.

If you are a patient or caregiver, click the PATIENT button.

CONTINUE ▸

You are now leaving the ServierONE website to go to a Third Party Resource. Do you want to proceed?

Yes ▸